+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of ABO blood group in patients with early stage cervical cancer treated with radical hysterectomy with pelvic node dissection



Prognostic value of ABO blood group in patients with early stage cervical cancer treated with radical hysterectomy with pelvic node dissection



Tumour Biology 37(6): 7421-7430



This study aimed to evaluate the prognostic value of ABO blood groups in early-stage cervical cancer patients. The cohort included 413 patients diagnosed with stages IA2-IB1 cervical cancer who received a radical hysterectomy between 2002 and 2014. The 5-year recurrence-free survival (RFS) and overall survival (OS) were 93.13 and 96.81 % for blood group O, 87.68 and 88.22 % for blood group A, 81.66 and 89.40 % for blood group B, and 83.12 and 94.12 % for blood group AB groups, respectively. Patients were stratified for analysis as either blood group O or non-O. The 5-year RFS and OS were 93.13 and 96.81 % for blood group O and 83.66 and 89.76 % for blood group non-O, respectively. In multivariate analysis, age (P = 0.025), histology (P = 0.020), and deep stromal invasion (P = 0.006) were independent adverse prognostic factors for RFS, while the statistically significant independent prognostic factors for OS were age (P = 0.007) and parametrial involvement (P < 0.001). The Cox model did not show any significant effects of non-O blood group on survival outcome. However, a time-varying-effect Cox model revealed that the non-O blood group was associated with a worse RFS (hazard ratio (HR) 2.69, 95 % confidence interval (95%CI) 1.12-6.46, P = 0.017) and OS (HR 3.13, 95%CI 0.88-11.16, P = 0.053) during the first 5 years. These findings suggest that early-stage cervical cancer patients with a non-O blood group have poorer RFS than the O blood group, which is evidence during the first 5 years.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637469

Download citation: RISBibTeXText

PMID: 26678885

DOI: 10.1007/s13277-015-4626-1


Related references

Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. International Journal of Gynecological Cancer 10(4): 305-312, 2001

Number and distribution of pelvic lymph nodes and effect of surgical pathologic factors on pelvic lymph node status in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection. European Journal of Gynaecological Oncology 27(5): 463-466, 2006

Prognostic factors in node-positive patients with stage IB-IIB cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 93(2): 130-135, 2006

Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection - an analysis with mathematical statistics. International Journal of Gynecological Cancer 3(4): 219-225, 1993

Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection. Journal of Obstetrics and Gynaecology Research 33(6): 840-848, 2007

Late Recurrence of Early Stage Cervical Cancer more than 3 Years after Radical Hysterectomy with Pelvic Node Dissection. Oncology Research and Treatment 40(5): 270-276, 2017

Surgical pathologic factors in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection: association with administration of adjuvant radiotherapy and effect on survival. European Journal of Gynaecological Oncology 27(6): 573-578, 2007

Comparison of Type III Laparoscopic Radical Hysterectomy with Pelvic Lymph Node Dissection and Type III Abdominal Radical Hysterectomy with Pelvic Lymph Node Dissection in the Management of Stage Ib-IIa Cervical Cancer. Journal of Minimally Invasive Gynecology 15(6): 85-86, 2008

Renal Calyceal Rupture in a Patient With Early Stage Cervical Carcinoma Treated by Robot-Assisted Radical Hysterectomy and Pelvic Node Dissection. Journal of Minimally Invasive Gynecology 22(6s): S252-S253, 2016

Impact of time interval between radical hysterectomy with pelvic node dissection and initial adjuvant therapy on oncological outcomes of early stage cervical cancer. Journal of Gynecologic Oncology 28(4): E42, 2018

Radiation therapy in patients undergoing radical hysterectomy and pelvic node dissection for early stages of cervical cancer. Nori, D And B S Hilaris (Ed) Radiation Therapy Of Gynecological Cancer Xi+431p Alan R Liss, Inc : New York, New York Usa Illus 369-376, 1987

The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy. International Journal of Gynecological Cancer 22(3): 490-497, 2012

Sentinel lymph node identification in patients with early stage cervical cancer undergoing radical hysterectomy and pelvic lymphadenectomy. Chinese Medical Journal 117(6): 867-870, 2004

A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection. Gynecologic Oncology 144(3): 536-540, 2017

Recurrence patterns in patients with early stage cervical cancer treated with radical hysterectomy and external pelvic irradiation. Anticancer Research 15(3): 1071-1077, 1995